Thư viện tri thức trực tuyến
Kho tài liệu với 50,000+ tài liệu học thuật
© 2023 Siêu thị PDF - Kho tài liệu học thuật hàng đầu Việt Nam

Tài liệu Báo cáo khoa học: Plasticity of S2–S4 specificity pockets of executioner caspase-7 revealed
Nội dung xem thử
Mô tả chi tiết
Plasticity of S2–S4 specificity pockets of executioner
caspase-7 revealed by structural and kinetic analysis
Johnson Agniswamy, Bin Fang and Irene T. Weber
Department of Biology, Molecular Basis of Disease, Georgia State University, Atlanta, GA, USA
Caspases, the key effector molecules in apoptosis, are
potential targets for pharmacological modulation of
cell death. Uncontrolled apoptosis due to enhanced
caspase activity occurs in nerve crush injury, stroke
and neurodegenerative diseases such as Alzheimer’s,
Parkinson’s and Huntington’s diseases [1–3]. On the
other hand, inadequate caspase activity is implicated in
cancer, autoimmune diseases and viral infections [4–6],
and a number of potential drugs are being developed
for selective induction of apoptosis in cancer cells [7,8].
The substrate-based peptide inhibitor zVAD-fmk provides substantial protection against stroke, myocardial
infarction, osteoarthritis, hepatic injury, sepsis, and
amyotrophic lateral sclerosis in animal models [9–11].
Small nonpeptide inhibitors are preferred for their
superior metabolic stability and cell permeability. Two
nonpeptide inhibitors are currently in phase II clinical
trials: IDN6556 for treatment of acute-tissue injury
disease and liver diseases [12], and VX-740 for treatment of rheumatoid arthritis [13]. Knowledge of the
molecular basis for substrate specificity of caspases is
critical for design of therapeutic agents for selective
control of cell death.
Caspases are cysteine proteases that hydrolyze the
peptide bond after an aspartate residue [14–17]. Thirteen human caspases have been cloned and characterized to varying extents [18,19]. Caspases are classified
into three groups based on their function and
Keywords
allosteric site; apoptosis; cysteine protease;
enzyme
Correspondence
I. T. Weber, Department of Biology, Georgia
State University, PO Box 4010, Atlanta,
GA 30302, USA
Fax: +1 404 413 5301
Tel: +1 404 413 5411
E-mail: [email protected]
Database
The atomic coordinates and structure
factors have been deposited in the Protein
Data Bank under the accession codes 2QL5
for caspase-7 ⁄ DMQD, 2QL9 for caspase-7 ⁄
DQMD, 2QLF for caspase-7 ⁄ DNLD, 2QL7
for caspase-7 ⁄ IEPD, 2QLB for caspase-7 ⁄
ESMD, and 2QLJ for caspase-7 ⁄ WEHD
(Received 18 April 2007, revised 3 July
2007, accepted 17 July 2007)
doi:10.1111/j.1742-4658.2007.05994.x
Many protein substrates of caspases are cleaved at noncanonical sites in
comparison to the recognition motifs reported for the three caspase subgroups. To provide insight into the specificity and aid in the design of
drugs to control cell death, crystal structures of caspase-7 were determined
in complexes with six peptide analogs (Ac-DMQD-Cho, Ac-DQMD-Cho,
Ac-DNLD-Cho, Ac-IEPD-Cho, Ac-ESMD-Cho, Ac-WEHD-Cho) that
span the major recognition motifs of the three subgroups. The crystal
structures show that the S2 pocket of caspase-7 can accommodate diverse
residues. Glu is not required at the P3 position because Ac-DMQD-Cho,
Ac-DQMD-Cho and Ac-DNLD-Cho with varied P3 residues are almost as
potent as the canonical Ac-DEVD-Cho. P4 Asp was present in the better
inhibitors of caspase-7. However, the S4 pocket of executioner caspase-7
has alternate regions for binding of small branched aliphatic or polar residues similar to those of initiator caspase-8. The observed plasticity of the
caspase subsites agrees very well with the reported cleavage of many proteins at noncanonical sites. The results imply that factors other than the
P4–P1 sequence, such as exosites, contribute to the in vivo substrate specificity of caspases. The novel peptide binding site identified on the molecular
surface of the current structures is suggested to be an exosite of caspase-7.
These results should be considered in the design of selective small molecule
inhibitors of this pharmacologically important protease.
Abbreviation
PARP, poly(ADP-ribose) polymerase.
4752 FEBS Journal 274 (2007) 4752–4765 ª 2007 The Authors Journal compilation ª 2007 FEBS